Literature DB >> 16299781

Differences and similarities of adenocarcinomas of the esophagus and esophagogastric junction.

W A Marsman1, G N J Tytgat, F J W ten Kate, J J B van Lanschot.   

Abstract

During the last few decades there has been an alarming rise in the incidence of tumors originating at the esophagogastric junction (EGJ) [1]. The reason for this is unknown. Tumors of the EGJ can be categorized in two types of cancer divided according to their anatomical origin: distal esophageal adenocarcinoma and adenocarcinoma of the gastric cardia. However, due to their location, in the transitional zone of the esophagus and stomach, there is constant debate about the proper classification, staging, and management of these tumors. The etiology of distal esophageal adenocarcinoma is clearly related to gastroesophageal reflux disease (GERD) and the development of a Barrett's esophagus [2]. The etiology of adenocarcinoma of the gastric cardia is less well understood. In the present paper, we will discuss the clinical characteristics and clinical management of esophagogastric tumors. Special attention will be given to differences and similarities of adenocarcinomas of the gastric cardia and distal esophagus. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 16299781     DOI: 10.1002/jso.20358

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  11 in total

Review 1.  Palliative chemotherapy and targeted therapies for esophageal and gastroesophageal junction cancer.

Authors:  Vincent T Janmaat; Ewout W Steyerberg; Ate van der Gaast; Ron Hj Mathijssen; Marco J Bruno; Maikel P Peppelenbosch; Ernst J Kuipers; Manon Cw Spaander
Journal:  Cochrane Database Syst Rev       Date:  2017-11-28

2.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

3.  Survival for oesophageal, stomach and small intestine cancers in Europe 1999-2007: Results from EUROCARE-5.

Authors:  L A Anderson; A Tavilla; H Brenner; S Luttmann; C Navarro; A T Gavin; B Holleczek; B T Johnston; M B Cook; F Bannon; M Sant
Journal:  Eur J Cancer       Date:  2015-09-26       Impact factor: 9.162

4.  Comparison of long-term outcomes of endoscopic submucosal dissection and surgery for esophagogastric junction adenocarcinoma.

Authors:  Eun Jeong Gong; Do Hoon Kim; Ji Yong Ahn; Kee Wook Jung; Jeong Hoon Lee; Kee Don Choi; Ho June Song; Gin Hyug Lee; Hwoon-Yong Jung; Hee Sung Kim; In-Seob Lee; Beom Su Kim; Moon-Won Yoo; Sung Tae Oh; Jeong Hwan Yook; Byung Sik Kim
Journal:  Gastric Cancer       Date:  2016-12-19       Impact factor: 7.370

5.  RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.

Authors:  Daniel V T Catenacci; Gustavo Cervantes; Soheil Yala; Erik A Nelson; Essam El-Hashani; Rajani Kanteti; Mohamed El Dinali; Rifat Hasina; Johannes Brägelmann; Tanguy Seiwert; Michele Sanicola; Les Henderson; Tatyana A Grushko; Olufunmilayo Olopade; Theodore Karrison; Yung-Jue Bang; Woo Ho Kim; Maria Tretiakova; Everett Vokes; David A Frank; Hedy L Kindler; Heather Huet; Ravi Salgia
Journal:  Cancer Biol Ther       Date:  2011-07-01       Impact factor: 4.742

Review 6.  Carcinoma of the gastroesophageal junction in Chinese patients.

Authors:  Qin Huang
Journal:  World J Gastroenterol       Date:  2012-12-28       Impact factor: 5.742

7.  Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.

Authors:  Z A Wainberg; L-S Lin; B DiCarlo; K M Dao; R Patel; D J Park; H-J Wang; R Elashoff; N Ryba; J R Hecht
Journal:  Br J Cancer       Date:  2011-08-02       Impact factor: 7.640

8.  [The surgical treatment of adenocarcinoma of the gastroesophageal junction: Moroccan experience through a series of 149 cases].

Authors:  Meryem Glaoui; Sarah Naciri; Samia Ghanem; Abdelkader Belkouchi; Hassan Errihani
Journal:  Pan Afr Med J       Date:  2011-03-30

9.  Neoadjuvant chemoradiation therapy for resectable esophago-gastric adenocarcinoma: a meta-analysis of randomized clinical trials.

Authors:  Tao Fu; Zhao-De Bu; Zi-Yu Li; Lian-Hai Zhang; Xiao-Jiang Wu; Ai-Wen Wu; Fei Shan; Xin Ji; Qiu-Shi Dong; Jia-Fu Ji
Journal:  BMC Cancer       Date:  2015-04-28       Impact factor: 4.430

10.  Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.

Authors:  Yoko Tomita; Max Moldovan; Rachael Chang Lee; Amy Hc Hsieh; Amanda Townsend; Timothy Price
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.